{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:08:12Z","timestamp":1793052492776,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-05752-9","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T12:25:10Z","timestamp":1750335910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world adherence and persistence with medication among men with lower urinary tract symptoms owing to benign prostatic hyperplasia in Japan: a clinical prospective study"],"prefix":"10.1007","volume":"43","author":[{"given":"Toshiyuki","family":"Kamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8411-3641","authenticated-orcid":false,"given":"Hiromasa","family":"Tsukino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"5752_CR1","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.urology.2008.03.057","volume":"72","author":"JK Parsons","year":"2008","unstructured":"Parsons JK, Bergstrom J, Silberstein J, Barrett-Connor E (2008) Prevalence and characteristics of lower urinary tract symptoms in men aged\u2009>\u2009or =\u200980 years. Urology 72:318\u2013321","journal-title":"Urology"},{"key":"5752_CR2","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/iju.15454","volume":"31","author":"T Mitsui","year":"2024","unstructured":"Mitsui T, Sekido N, Masumori N, Haga N, Omae K, Saito M, Kubota Y, Sakakibara R, Yoshida M, Takahashi S (2024) Prevalence and impact on daily life of lower urinary tract symptoms in japan: results of the 2023 Japan community health survey (JaCS 2023). Int J Urol 31:747\u2013754","journal-title":"Int J Urol"},{"key":"5752_CR3","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/iju.13401","volume":"24","author":"Y Homma","year":"2017","unstructured":"Homma Y, Gotoh M, Kawauchi A, Kojima Y, Masumori N, Nagai A, Saitoh T, Sakai H, Takahashi S, Ukimura O, Yamanishi T, Yokoyama O, Yoshida M, Maeda K (2017) Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Int J Urol 24:716\u2013729","journal-title":"Int J Urol"},{"key":"5752_CR4","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44\u201347","journal-title":"Value Health"},{"key":"5752_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1185\/03007995.2014.968704","volume":"31","author":"Z Hakimi","year":"2015","unstructured":"Hakimi Z, Johnson M, Nazir J, Blak B, Odeyemi IA (2015) Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data. Curr Med Res Opin 31:43\u201350","journal-title":"Curr Med Res Opin"},{"key":"5752_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/ijcp.12241","volume":"68","author":"JS Koh","year":"2014","unstructured":"Koh JS, Cho KJ, Kim HS, Kim JC (2014) Twelve-month medication persistence in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int J Clin Pract 68:197\u2013202","journal-title":"Int J Clin Pract"},{"key":"5752_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/0149-2918(95)80009-3","volume":"17","author":"R Yasumoto","year":"1995","unstructured":"Yasumoto R, Kawanishi H, Tsujino T, Tsujita M, Nishisaka N, Horii A, Kishimoto T (1995) Clinical evaluation of long-term treatment using cernitin pollen extract in patients with benign prostatic hyperplasia. Clin Ther 17:82\u201387","journal-title":"Clin Ther"},{"key":"5752_CR8","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cct.2007.07.008","volume":"28","author":"P Siami","year":"2007","unstructured":"Siami P, Roehrborn CG, Barkin J, Damiao R, Wyczolkowski M, Duggan A, Major-Walker K, Morrill BB, CombAT study group (2007) Combination therapy with dutasteride and Tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the combat (Combination of avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials 28:770\u2013779","journal-title":"Contemp Clin Trials"},{"key":"5752_CR9","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bju.13033","volume":"116","author":"CG Roehrborn","year":"2015","unstructured":"Roehrborn CG, Oyarzabal Perez I, Roos EP, Calomfirescu N, Brotherton B, Wang F, Palacios JM, Vasylyev A, Manyak MJ (2015) Efficacy and safety of a fixed-dose combination of dutasteride and Tamsulosin treatment (Duodart(\u00ae)) compared with watchful waiting with initiation of Tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-na\u00efve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. Br J Urol Int 116:450\u2013459","journal-title":"Br J Urol Int"},{"key":"5752_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1442-2042.2012.03165.x","volume":"20","author":"N Masumori","year":"2013","unstructured":"Masumori N, Tsukamoto T, Horita H, Sunaoshi K, Tanaka Y, Takeyama K, Sato E, Miyao N (2013) \u03b11-blocker Tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study. Int J Urol 20:421\u2013428","journal-title":"Int J Urol"},{"key":"5752_CR11","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.2147\/PPA.S110440","volume":"10","author":"N Masumori","year":"2016","unstructured":"Masumori N, Tsukamoto T, Shibuya A, Miyao N, Kunishima Y, Iwasawa A (2016) Three-year outcome analysis of alpha 1-blocker Naftopidil for patients with benign prostatic hyperplasia in a prospective multicenter study in Japan. Patient Prefer Adherence 10:1309\u20131316","journal-title":"Patient Prefer Adherence"},{"key":"5752_CR12","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1111\/iju.12915","volume":"22","author":"T Yamanishi","year":"2015","unstructured":"Yamanishi T, Kaga K, Fuse M, Shibata C, Kamai T, Uchiyama T (2015) Six-year follow up of silodosin monotherapy for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: what are the factors for continuation or withdrawal? Int J Urol 22:1143\u20131148","journal-title":"Int J Urol"},{"key":"5752_CR13","doi-asserted-by":"crossref","unstructured":"Tanaka Y, Tanuma Y, Masumori N (2017) The persistence of silodosin monotherapy and the reasons for withdrawal from treatment of previously untreated Japanese patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Adv Urol 2017: 4842025","DOI":"10.1155\/2017\/4842025"},{"key":"5752_CR14","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.juro.2009.01.033","volume":"181","author":"MB Nichol","year":"2009","unstructured":"Nichol MB, Knight TK, Wu J, Barron R, Penson DF (2009) Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol 181:2214\u20132221","journal-title":"J Urol"},{"key":"5752_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5414\/CP203549","volume":"58","author":"C Eisen","year":"2020","unstructured":"Eisen C, Lulic Z, Palacios-Moreno JM, Adalig B, Hennig M, Cortes V, Gilg F, Kostev K (2020) Persistence and adherence to dutasteride\/tamsulosin fixed-dose versus free-combination alpha blocker\/5ARI therapy in patients with benign prostate hyperplasia in Germany. Int J Clin Pharmacol Ther 58:37\u201349","journal-title":"Int J Clin Pharmacol Ther"},{"key":"5752_CR16","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1016\/S0022-5347(05)65189-0","volume":"167","author":"JJ de la Rosette","year":"2002","unstructured":"de la Rosette JJ, Kortmann BB, Rossi C, Sonke GS, Floratos DL, Kiemeney LA (2002) Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. J Urol 167:1734\u20131739","journal-title":"J Urol"},{"key":"5752_CR17","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1097\/01.ju.0000170235.22776.1a","volume":"174","author":"M Ghei","year":"2005","unstructured":"Ghei M, Malone-Lee J (2005) Using the circumstances of symptom experience to assess the severity of urgency in the overactive bladder. J Urol 174:972\u2013976","journal-title":"J Urol"},{"key":"5752_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/iju.12129","volume":"20","author":"T Imamura","year":"2013","unstructured":"Imamura T, Ishizuka O, Nishizawa O (2013) Cold stress induces lower urinary tract symptoms. Int J Urol 20:661\u2013669","journal-title":"Int J Urol"},{"key":"5752_CR19","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/S0022-5347(05)68062-7","volume":"162","author":"G Geirsson","year":"1999","unstructured":"Geirsson G, Lindstr\u00f6m S, Fall M (1999) The bladder cooling reflex and the use of cooling as stimulus to the lower urinary tract. J Urol 162:1890\u20131896","journal-title":"J Urol"},{"key":"5752_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00345-025-05641-1","volume":"23","author":"T Soda","year":"2025","unstructured":"Soda T, Yamauchi T, Otsuka H, Makita N, Okada T (2025) Pharmacotherapy for BPH-related LUTS: associations between medication patterns, persistence, and treatment failure. World J Urol 23:245","journal-title":"World J Urol"},{"key":"5752_CR21","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.eururo.2014.11.006","volume":"68","author":"L Cindolo","year":"2014","unstructured":"Cindolo L, Pirozzi L, Fanizza C, Romero M, Tubaro A, Autorino R, De Nunzio C, Schips L (2014) Drug adherence and clinical outcomes for patients under Pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol 68:418\u2013425","journal-title":"Eur Urol"},{"key":"5752_CR22","doi-asserted-by":"crossref","unstructured":"Cindolo L, Pirozzi L, Sountoulides P, Fanizza C, Romero M, Castellan P, Antonelli A, Simeone C, Tubaro A, de Nunzio C, Schips L (2015) Patient\u2019s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy? BMC Urol 21: 96.","DOI":"10.1186\/s12894-015-0090-x"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05752-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05752-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05752-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:51:50Z","timestamp":1767966710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05752-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5752"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05752-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6256455\/v1","asserted-by":"object"}]},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval was obtained in accordance with the principles of Declaration of Helsinki by the ethics committee, the Institutional Review Board of Miyazaki University Faculty of Medicine.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained in the form of opt-out on the website. Those who opted out were excluded.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"377"}}